UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000017967
Receipt No. R000020780
Official scientific title of the study Clinical study of gemcitabine plus docetaxel in patient with refractory bone and soft tissue sarcomas
Date of disclosure of the study information 2015/06/25
Last modified on 2018/06/20 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Clinical study of gemcitabine plus docetaxel in patient with refractory bone and soft tissue sarcomas
Title of the study (Brief title) GEM+DTX in patient with sarcomas
Region
Japan

Condition
Condition bone and soft tissue sarcoma
Classification by specialty
Orthopedics
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Chemotherapy using Ifosfamide, doxorubicin, cisplatin, etoposide, methotrexateis provided for bone and soft tissue sarcomas conventionally. There are some clinical problems that conventional chemotherapy resist tumor, myelosupression and necessity of hospitalization. Gemcitabine and docetaxel are already approved in Japan. The efficacy of chemotherapy with gemcitabine and docetaxel as a second line for refractory bone and soft tissue sarcomas was reported. Chemotherapy with gemcitabine and docetaxel had relatively low risk for myelosupression, this treatment can be indicated in daily out patient clinic. We plan a clinical study of gemcitabine and docetaxel for patient with refractory bone and soft tissue sarcomas.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Others
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes tumor response
survival
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 From June 25th, 2015 to December 31th, 2018
Gemcitabine675mg/m2, day1, day8
Docetaxel75mg/m2, day8
3 weeks or more interval
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria Establishment of histopathological diagnosis of bone and soft tissue sarcomas
Non responder case with previous 1st line chemotherapy
Patient who had enough understanding after explanation of this study and presented document of agreement by their free will
Key exclusion criteria Patient with severe liver or renal dysfunction
Patient with severe interstitial pneumonitis
PS4
Pregnant woman
Patient who was decided as incompatible by the principal investigator of this study
Target sample size 10

Research contact person
Name of lead principal investigator Torigoe Tomoaki
Organization Juntendo University Urayasu Hospital
Division name Orthopaedic Surgery
Address 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021
TEL 047-353-3111
Email ttorigoe@juntendo.ac.jp

Public contact
Name of contact person Torigoe Tomoaki
Organization Juntendo University Urayasu Hospital
Division name Orthopaedic Surgery
Address 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021
TEL 047-353-3111
Homepage URL
Email ttorigoe@juntendo.ac.jp

Sponsor
Institute Juntendo University Urayasu Hospital
Institute
Department

Funding Source
Organization Juntendo University Urayasu Hospital
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 06 Month 25 Day

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 06 Month 11 Day
Anticipated trial start date
2015 Year 06 Month 25 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2015 Year 06 Month 18 Day
Last modified on
2018 Year 06 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000020780